Ayn serves as AI Analyst at Emerj - covering artificial intelligence use-cases and trends across industries. She previously held various roles at Accenture. Several factors have contributed to the advancement of AI in the pharmaceutical industry. These factors include the increase in the size of and the greater variety of types of biomedical datasets, as a result of the increased usage of electronic health records. This article intends to provide business leaders in the pharmacy space with an idea of what they can currently expect from Ai in their industry.

Adrienne Gormley, head of EMEA and VP of global customer experience at Dropbox "There is a lot of attention, rightfully so, on AI having the ability to predict user needs and analyse data patterns in a more effective manner. For instance, machine intelligence can surface the content you will need for a meeting or recognise images, so you don't have to remember file names. Machines can do the more structured tasks, which will enable humans to focus on the work that matters. "In the future, we will see AI take on more complicated tasks. As AI continues to develop, humans will have more natural and seamless interactions.

The dietary supplements category has its share of fad ingredients or formulations, and for years the industry was able to maintain high levels of new product launches thanks to a steady flow of new ingredients coming onto the market. But increased media and consumer scrutiny and the long shadow of the NDI process does seem to have had a chilling effect on the introduction of new ingredients launches over the past decade. Back in November 2015, Colin Watts, then-CEO of The Vitamin Shoppe, said: "I think the issue that we are facing this year is […] the rate of new ingredients, new products, new forms that are coming into the market are less than we've seen in the past. "And so when there isn't a lot of new in this category in particular, especially the retailer ends up taking a little bit earlier of a hit in that front, because the customer just doesn't have a reason to come in and see something new that's going on" Innovation is still occurring, of course: You can point to innovation in delivery formats, in the supply chain and around the science, but one of greatest benefits to the industry has come from technology. The Internet was barely a thing when the Dietary Supplement Health & Education Act (DSHEA) was signed into law in 1994, and now every single brand has an online presence.

The European Investment Bank today (November 29th) agreed a EUR 30 million facility to support investment by Dublin based biotech company, Nuritas, to further increase and accelerate development of artificial intelligence and DNA analysis to improve global healthcare. Representing the first direct EIB financing for an Irish biotech company, the new support will allow the company to access tranched financing as required to scale up the development of the rapidly growing company. Future investment by the company backed by the EIB will scale up development of new therapeutics in areas of interest including anti-aging, anti-inflammatory and diabetes treatment. "Nuritas has already demonstrated through PeptAIde, their first product launch this year, how the discovery of healthcare products can be rapidly accelerated using artificial intelligence. During due diligence over recent months the EIB has been impressed by their innovative use of technology and the number of global deals already achieved and they now become the first Irish biotech firm to benefit from the EIB's dedicated European Growth Finance Facility. Our goal is to find innovative and fast-growing companies so that we ensure they can benefit from access to long-term financing under the new initiative and Nuritas fits this bill perfectly. We look forward to working with other innovative and fast growing companies to ensure they can benefit from access to long-term financing under the new initiative. This new EUR 30 million support from the European Investment Bank will enable Nuritas to expand and commercialise even faster." said Andrew McDowell, European Investment Bank Vice President.

By 2050, the US population aged 65 and older is projected to reach 83.7M, almost double its population in 2012. To combat the aging process and help people lead longer and healthier lives, pharmaceutical corporates and tech giants alike have begun investing in startups that are specifically aiming to tackle the root causes of aging or age-related diseases. In 2013, Google officially launched Calico Life Sciences. Calico bills itself as a research and development company focused on interventions that extend life. And last year, Jeff Bezos' Bezos Expeditions invested in UNITY Biotechnology which designs therapeutics to prevent, halt, or reverse diseases of aging.

Bono and The Edge are excited by Nuritas' potential for impact and profitability. Try to imagine walking into your local grocery store ten years from now. You head towards the back, as you've done countless times before, to snatch a handful of your favorite cereal bars. Only this time, the packaging looks a bit different. You notice that there are two new versions, each with a label below the brand name.

Bono and The Edge are excited by Nuritas' potential for impact and profitability. Try to imagine walking into your local grocery store ten years from now. You head towards the back, as you've done countless times before, to snatch a handful of your favorite cereal bars. Only this time, the packaging looks a bit different. You notice that there are two new versions, each with a label below the brand name.

The first step of the partnership will see Nuritas, a biotech and R&D start-up that uses artificial intelligence and new technologies for the discovery of novel food and health ingredients, grant an exclusive royalty-based license to BASF to commercialise one of its existing peptides. A second part of the deal will focus on the discovery of new functional peptides, based on health areas that are strategically important to BASF, using Nuritas' technological expertise and AI platform. According to BASF, peptide networks of focus in the collaboration will be natural, food-derived, patented and of significant benefit to health – including peptides that bring about anti-inflammatory responses. "Cooperating with an innovative and agile start-up like Nuritas enables us to further expand our already broad portfolio of health solutions," commented Saori Dubourg, head of BASF's Nutrition & Health Business. Nuritas' unique platform combines DNA analysis and artificial intelligence (AI) to predict, unlock, and validate peptides from natural sources.